MedPath

[225Ac]Ac-PSMA-R2 Advanced Drug Monograph

Published:May 19, 2025

Generic Name

[225Ac]Ac-PSMA-R2

[225Ac]Ac-PSMA-R2: An Investigational Radioligand Therapy for Prostate Cancer

1. Introduction to [225Ac]Ac-PSMA-R2

[[225Ac]Ac-PSMA-R2 is an investigational radioligand therapy (RLT) representing a novel approach in the management of prostate cancer.1 This therapeutic agent is a conjugate composed of two principal components: PSMA-R2, a ligand specifically designed to target the Prostate-Specific Membrane Antigen (PSMA), and Actinium-225 ($^{225}$Ac), a potent alpha-emitting radionuclide.1 PSMA is a transmembrane protein that is significantly overexpressed on the surface of prostate cancer cells, and its expression levels often correlate with tumor aggressiveness and metastatic potential, making it an attractive molecular target for directed therapies.3 Actinium-225 is chosen for its high linear energy transfer (LET) and short particle range, characteristics that theoretically confer a high degree of cytotoxicity to targeted cells with limited damage to surrounding healthy tissue.3]

[The therapeutic rationale for [225Ac]Ac-PSMA-R2 centers on the precise delivery of highly damaging alpha radiation directly to PSMA-expressing prostate cancer cells, including those forming metastatic lesions.1 This targeted approach aims to maximize tumor cell kill while minimizing systemic toxicity. The agent is currently under investigation for patients with both metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).1 The mCRPC setting, particularly in heavily pre-treated patients, presents a significant clinical challenge due to the common development of resistance to standard therapies and limited subsequent treatment options.2 Targeted alpha therapies such as [225Ac]Ac-PSMA-R2 offer a promising strategy to potentially overcome these resistance mechanisms.3]

[[225Ac]Ac-PSMA-R2 is being developed by Novartis Pharmaceuticals and is also identified by the code AAA-802.7 It is currently in Phase I/II clinical development and is considered a new molecular entity.1 The development of [225Ac]Ac-PSMA-R2, featuring a distinct ligand from the more extensively studied PSMA-617, suggests a strategic endeavor by Novartis to potentially refine and improve upon existing PSMA-targeted RLTs. The selection of Actinium-225, an alpha-emitter, over beta-emitters like Lutetium-177 (though a Lutetium-177 labeled PSMA-R2, AAA602, is also in development 9), for this particular iteration (AAA-802) underscores an intent to leverage the pronounced cytotoxicity of alpha particles. This may be particularly advantageous in challenging prostate cancer scenarios, such as advanced or resistant disease, where higher cell-killing potency is desired. The existence of multiple PSMA ligands (e.g., PSMA-617, PSMA-I&T, PSMA-R2) and various radioisotopes ($^{177}$Lu, $^{225}$Ac) in the broader research landscape reflects ongoing efforts to optimize the therapeutic index of RLTs by enhancing tumor targeting, diminishing off-target effects, and increasing overall efficacy. PSMA-R2 itself is described as a "patented alternative" to $^{177}$Lu-PSMA-617, with potential enhancements in targeting efficiency and biodistribution characteristics.10 Coupling such a potentially improved ligand with a highly potent alpha-emitter like $^{225}$Ac could represent a significant advancement in the field.]

[**Table 1: Overview of [225Ac]Ac-PSMA-R2**]

[| Feature | Description |]

[| :--- | :--- |]

[| **Generic Name** | [225Ac]Ac-PSMA-R2 |]

[| **Other Names/Code Names** | AAA-802 8 |]

[| **Developer** | Novartis Pharmaceuticals 7 |]

[| **Therapeutic Class** | Antineoplastics, Drug conjugates, Radioisotopes, Radiopharmaceuticals, Targeted Alpha Therapy 1 |]

[| **Mechanism of Action** | PSMA-targeted delivery of Actinium-225, which emits alpha particles leading to DNA double-strand breaks and subsequent cancer cell death.1 |]

[## 2. Mechanism of Action]

[The therapeutic effect of [225Ac]Ac-PSMA-R2 is achieved through a dual-component mechanism involving specific targeting of prostate cancer cells by the PSMA-R2 ligand, followed by the cytotoxic action of the alpha-particle emissions from Actinium-225.]

[**PSMA Targeting by PSMA-R2 Ligand:**]

[The PSMA-R2 component is a molecular ligand meticulously designed to bind with high affinity and specificity to the Prostate-Specific Membrane Antigen (PSMA).1 PSMA is a type II transmembrane glycoprotein that exhibits significantly elevated expression on the surface of the vast majority of prostate cancer cells. Its expression levels are often correlated with tumor grade, advanced stage, metastatic dissemination, and the development of castration-resistant disease.1 While PSMA is present in some normal tissues, such as the salivary glands, kidneys, and small intestine, its expression is considerably lower than in malignant prostate tissue, providing a therapeutic window for targeted therapies.4 Upon administration, the PSMA-R2 ligand circulates and selectively binds to PSMA on prostate cancer cells, thereby concentrating the attached radionuclide at the tumor sites.1]

[**Role of Actinium-225 ($^{225}$Ac) as an Alpha-Emitter:**]

[Actinium-225 is a potent radionuclide that undergoes a decay cascade, emitting a total of four high-energy alpha particles per decay of the parent $^{225}$Ac atom.3 Alpha particles are helium nuclei characterized by their high Linear Energy Transfer (LET), meaning they deposit a substantial amount of energy over a very short distance within tissue, typically spanning only a few cell diameters (approximately 40-100 µm).5 This high LET results in dense ionization events along the particle's track, leading to complex and highly lethal damage to cellular structures, most critically the DNA.3]

[Cellular Effects and Advantages of Targeted Alpha Therapy (TAT):]

[The primary mechanism by which alpha particles induce cell death is through the creation of irreparable double-stranded DNA breaks (DSBs).3 These complex DSBs are particularly challenging for cancer cells to repair, often leading to cell cycle arrest and apoptosis. Several advantages are associated with TAT utilizing alpha-emitters like $^{225}$Ac:]

  • High Cytotoxicity: Due to the dense ionization and complex damage inflicted, significantly fewer alpha particle "hits" (traversals through a cell nucleus) are required to induce cell death compared to beta-emitters or gamma radiation.[3]
  • Efficacy in Resistant and Hypoxic Cells: Alpha particles can effectively kill cancer cells that may be resistant to other forms of therapy, including chemotherapy and beta-particle RLT. Their efficacy is also largely independent of cellular oxygen levels, making them effective in hypoxic (low oxygen) regions of tumors, where conventional radiotherapy and some chemotherapies are less effective.[3]
  • Short Path Length and Targeted Effect: The short range of alpha particles ensures that their cytotoxic effects are highly localized to the targeted cancer cells and their immediate microenvironment. This minimizes radiation exposure to surrounding healthy tissues that do not express PSMA or express it at low levels, thereby potentially reducing systemic toxicity.[3] While the direct "bystander effect" (killing of adjacent non-targeted cells by mediators released from irradiated cells) is limited by the short particle range, a "crossfire effect" can occur where alpha particles emitted from one targeted cell can traverse and kill adjacent targeted tumor cells.

[Clinical studies involving PSMA-targeted alpha therapy with $^{225}$Ac have demonstrated encouraging efficacy in patients with mCRPC, including those who have become refractory to other treatments such as $^{177}$Lu-PSMA RLT.3 The development of [225Ac]Ac-PSMA-R2 represents a strategic "one-two punch" approach, combining a potentially optimized PSMA-targeting ligand (PSMA-R2) with the highly potent alpha-emitting radionuclide $^{225}$Ac. This strategy aims to maximize the eradication of tumor cells, particularly in the context of advanced and treatment-resistant prostate cancer, where beta-emitting radioligands might face limitations in efficacy. Standard PSMA-targeted beta-therapy, such as $^{177}$Lu-PSMA-617, has shown considerable clinical benefit, but not all patients achieve a response, and acquired resistance can emerge over time.3 Alpha emitters like $^{225}$Ac offer a more powerful cell-killing mechanism due to their high LET and the induction of complex DNA damage, which is less amenable to cellular repair mechanisms.3 If the PSMA-R2 ligand demonstrates superior tumor targeting, increased tumor retention, or more favorable pharmacokinetics compared to earlier-generation ligands 10, its conjugation with $^{225}$Ac could result in a more effective therapeutic agent. This is particularly relevant for patients who have previously failed other systemic therapies or those presenting with highly aggressive disease phenotypes. Such an approach is a logical evolution in the field of radiopharmaceutical development, focusing on the concurrent optimization of both the delivery system (the ligand) and the therapeutic payload (the radionuclide).]

[## 3. The PSMA-R2 Ligand: Characteristics and Potential Advantages]

[The PSMA-R2 ligand is a critical component of [225Ac]Ac-PSMA-R2, responsible for the selective delivery of Actinium-225 to prostate cancer cells. Its design and properties are key to the overall therapeutic profile of the radiopharmaceutical.]

[**Chemical Nature and Properties:**]

[PSMA-R2 is characterized as a urea-based ligand.10 Urea-based pharmacophores are well-established in the design of high-affinity inhibitors of PSMA, as they effectively mimic the substrate binding site of the enzyme. The PubChem database entry for Gallium ($^{68}$Ga) psma-R2 (Compound CID: 163203566) provides structural information for the ligand when chelated with Gallium-68, which is used for diagnostic imaging.15 According to this entry:]

  • The molecular formula for $^{68}$Ga-PSMA-R2 is C41​H60​BrGaN8​O15​.
  • The IUPAC name for $^{68}$Ga-PSMA-R2 is 2-carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gallium-68(3+).
  • The SMILES string representing $^{68}$Ga-PSMA-R2 is C1CN(CCN(CCN(CCN1CC(=O)NCCCCCC(=O)N(CCCCC@@HNC(=O)NC@@HC(=O)O)CC2=CC=C(C=C2)Br)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[68Ga+3]. The parent compound, which is the PSMA-R2 ligand itself without the gallium atom, is listed with CID 155464989.[15] Based on the formula for the gallium conjugate, the molecular formula for the PSMA-R2 ligand is presumed to be C41​H63​BrN8​O15​. PSMA-R2 is designed to target carboxypeptidase-II, an enzymatic activity associated with PSMA.[10]

[Comparison with other PSMA Ligands (e.g., PSMA-617, PSMA-I&T):]

[PSMA-R2 was developed as a patented alternative to other PSMA-targeting agents, such as $^{177}$Lu-PSMA-617, with the aim of achieving potential improvements in targeting efficiency and overall clinical outcomes.10 The urea-based structure of PSMA-R2 is reported to confer enhanced binding affinity for PSMA, which could translate to improved tumor targeting and retention.10 Preclinical studies conducted with $^{177}$Lu-PSMA-R2 have suggested an improved biodistribution profile compared to $^{177}$Lu-PSMA-617, which might lead to reduced off-target radiation exposure and consequently fewer associated toxicities.10 This is a critical consideration, as the therapeutic index of radioligand therapies is often limited by uptake in normal PSMA-expressing tissues.]

Dosimetry data obtained from studies using $^{68}$Ga-PSMA-R2 for imaging have shown relatively low uptake in the salivary glands (mean absorbed dose of 0.016 mGy/MBq) and lacrimal glands (0.008 mGy/MBq).[4] This is a particularly favorable finding, as xerostomia (dry mouth) resulting from salivary gland irradiation is a common and often dose-limiting side effect of PSMA-targeted therapies, especially with alpha-emitters like $^{225}$Ac. For instance, dosimetry estimates for $^{225}$Ac-PSMA-617 have indicated a much higher mean dose to salivary glands (2.3 Sv per 1 MBq).[17] If the favorable salivary gland dosimetry observed with $^{68}$Ga-PSMA-R2 translates to the $^{225}$Ac-PSMA-R2 conjugate, it could significantly mitigate this problematic side effect. While direct comparisons are complex due to different radionuclides and dosimetric assumptions, the initial data for PSMA-R2 are promising. It is important to note that while PSMA-617 and PSMA-I&T share similar PSMA-binding motifs and have shown comparable efficacy in some analyses, differences in their lipophilicity and dosimetry, particularly concerning renal uptake, have been observed.[18] PSMA-R2 aims to be part of a newer generation of PSMA ligands with potentially optimized pharmacokinetic and pharmacodynamic characteristics.

The emphasis on PSMA-R2's "enhanced binding affinity" and "optimized biodistribution" [10], combined with the encouraging preliminary dosimetry for its $^{68}$Ga-labeled counterpart [4], points towards Novartis's objective of developing a ligand that could offer a superior therapeutic window compared to earlier PSMA ligands. The development of novel PSMA ligands is primarily driven by the necessity to improve the benefit-risk profile of PSMA-targeted RLT. Key limitations of first-generation ligands include dose-limiting toxicities to critical normal organs, most notably the salivary glands (leading to xerostomia) and the kidneys. If PSMA-R2 genuinely possesses higher tumor affinity and/or retention, coupled with reduced accumulation or faster clearance from these critical normal organs, it could enable the delivery of higher radiation doses to tumors for a given level of systemic toxicity, thereby potentially enhancing therapeutic efficacy. Alternatively, it could lead to a reduction in side effects at tumor doses equieffective to those achieved with other ligands, thus improving patient quality of life. The favorable dosimetry of $^{68}$Ga-PSMA-R2 in salivary glands is a particularly significant observation, given that xerostomia is a major concern with $^{225}$Ac-PSMA-617.[3] Should [225Ac]Ac-PSMA-R2 maintain this advantageous salivary gland profile, it would represent a substantial clinical advantage.

Furthermore, PSMA-R2 is being developed within a theranostic framework. This involves using $^{68}Ga−PSMA−R2fordiagnosticimagingandpatientselection,whilethesameligandconjugatedtoatherapeuticradionuclide,suchasLutetium−177([^{177}$Lu]Lu-PSMA-R2, also known as AAA602) or Actinium-225 ([225Ac]Ac-PSMA-R2, AAA802), is used for treatment.[9] This theranostic pairing allows for a personalized medicine approach, where diagnostic imaging can predict which patients are most likely to benefit from the therapy and can also be used to monitor treatment response. The favorable biodistribution and clear imaging characteristics of $^{68}$Ga-PSMA-R2 [4] are crucial for its role as the diagnostic companion to the therapeutic versions, aiming to ensure that the sites of uptake seen on the PET scan accurately reflect the subsequent delivery sites of the therapeutic radiation dose.

4. Preclinical Evaluation

Preclinical studies form a foundational part of drug development, providing initial evidence of efficacy, safety, and pharmacokinetic properties before human trials. While specific, detailed preclinical results for [225Ac]Ac-PSMA-R2 (AAA-802) were noted as commencing in the USA in August 2023 [8], comprehensive published data directly pertaining to this exact compound are not extensively detailed in the provided information. However, insights can be drawn from general preclinical findings for other $^{225}$Ac-labeled PSMA agents and the $^{177}$Lu-labeled version of PSMA-R2.

Studies on various $^{225}$Ac-labeled PSMA agents, such as $^{225}$Ac-L1 (a different PSMA ligand), have demonstrated key characteristics relevant to the potential of [225Ac]Ac-PSMA-R2. These include specific uptake and cell killing in PSMA-positive prostate cancer cells and activity-dependent, specific inhibition of tumor growth in PSMA-positive xenograft models.[13] Furthermore, $^{225}$Ac-L1 showed an increased survival benefit in micrometastatic models when compared to its $^{177}$Lu-labeled counterpart, highlighting the potency of alpha-particle therapy.[13] However, these studies also identified potential off-target radiotoxicity, primarily affecting the kidneys and liver, with an estimated maximum tolerated activity for $^{225}$Ac-L1 of approximately 1 MBq/kg in mice.[13] Alpha-camera imaging of $^{225}Ac−L1revealedhighrenalcorticalaccumulationat2hourspost−injection,followedbyrelativelyfastclearanceby24hours.[13]Inadifferentcontext,studieswith[^{226}$Ac]Ac-crown-TATE, an agent targeting somatostatin receptors but using Actinium (with $^{226}$Ac as a theranostic pair for $^{225}Ac),demonstratedhightumoruptake(over30PreclinicalinvestigationsinvolvingtheLutetium−177labeledversionofthePSMA−R2ligand(^{177}$Lu-PSMA-R2) suggested an optimized biodistribution profile when compared to $^{177}$Lu-PSMA-617.[10] If these favorable biodistribution characteristics of the PSMA-R2 ligand are maintained when conjugated with Actinium-225, it could translate to an improved therapeutic index for [225Ac]Ac-PSMA-R2.

The progression of [225Ac]Ac-PSMA-R2 into clinical trials is supported by the general promise shown by other $^{225}$Ac-PSMA agents in preclinical models [13] and the broader theranostic concept employing Actinium isotopes.[12] A critical differentiating factor for [225Ac]Ac-PSMA-R2 will be whether the purported superior biodistribution of the PSMA-R2 ligand [10] results in a more favorable safety profile when combined with the highly potent $^{225}$Ac. This is particularly relevant concerning potential renal and salivary gland toxicities, which have been dose-limiting for other PSMA-targeted alpha therapies. Preclinical studies are essential for establishing proof-of-concept regarding efficacy and for identifying potential toxicities. The data from $^{225}$Ac-L1 studies [13] illustrate both the significant anti-tumor potential (tumor growth inhibition, survival benefit) and the inherent risks (off-target toxicity) associated with $^{225}$Ac-PSMA agents. The claim of "optimized biodistribution" for PSMA-R2 [10] is therefore of paramount importance. If [225Ac]Ac-PSMA-R2 can achieve comparable or superior tumor uptake relative to agents like $^{225}$Ac-L1 or $^{225}$Ac-PSMA-617, but with markedly lower accumulation in critical organs such as the kidneys and salivary glands, it could achieve a higher therapeutic index. The initiation of specific preclinical trials for [225Ac]Ac-PSMA-R2 in August 2023 [8] suggests that Novartis is actively generating or has reviewed such data to support the ongoing and planned clinical investigations.

5. Clinical Development Program for [225Ac]Ac-PSMA-R2

The clinical development of [225Ac]Ac-PSMA-R2 is being pursued through carefully designed trials aimed at evaluating its safety, tolerability, and efficacy across different prostate cancer patient populations. Two key trials, SatisfACtion and NeoPSMA, form the current backbone of this program.

The SatisfACtion Trial (NCT05983198 / CAAA802A12101 / EudraCT 2023-507672-52-00)

This is a Phase I/II, open-label, multi-center study designed to assess [225Ac]Ac-PSMA-R2 in adult men with PSMA-positive prostate cancer.[1] The trial incorporates a dose-escalation phase (Phase I) to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of [225Ac]Ac-PSMA-R2. This is followed by a dose-expansion phase (Phase II) to further evaluate anti-tumor activity at the established RDE.[1] Dose escalation decisions are made collaboratively by investigators and Novartis, based on emerging safety and tolerability data.[6]

The primary objectives are to characterize safety and tolerability and establish the MTD/RDE during dose escalation, and to evaluate anti-tumor activity (e.g., Overall Response Rate, ORR) during dose expansion.[1] Secondary objectives include assessing disease control rate, progression-free survival (PFS), overall survival (OS), and impact on quality of life.[1]

The trial enrolls patients with PSMA-positive disease, confirmed by $^{68}$Ga-PSMA-11 PET/CT, across three distinct cohorts (estimated total enrollment N=70 [7] or N=200 [20]):

  1. Group 1: Patients with mCRPC who have been previously treated with $^{177}Lu−labelledPSMA−targetedRLT(post−^{177}$Lu cohort).[2]
  2. Group 2: Patients with mCRPC who have not been previously treated with $^{177}Lu−labelledPSMA−targetedRLT(pre−^{177}$Lu or $^{177}$Lu-naïve cohort).[2]
  3. Group 3: Patients with mHSPC who have not been previously treated with $^{177}Lu−labelledPSMA−targetedRLT(pre−^{177}$Lu or $^{177}Lu−naı¨vecohort).[6,20,21]Allparticipantsmusthavereceivedprioranti−cancertreatmentandhavedocumentedprogressivedisease,adequateorganfunction,andeitherpriororchiectomyorongoingandrogendeprivationtherapy(ADT).[2,6]Keyexclusioncriteriaincludetheuseofotherinvestigationalagentsorsystemicanti−cancertherapywithin28daysofstarting[225Ac]Ac−PSMA−R2,uncontrolledpain,symptomaticCNSmetastasesorimpendingcordcompression,andrecentmajorcardiacevents.[6,20,22][225Ac]Ac−PSMA−R2isadministeredintravenously,withspecificdosingschedulesbeingevaluatedwithineachofthethreegroups.[2,6,7]TheSatisfACtiontrialcommencedonNovember7,2023,withanestimatedprimarycompletiondateofNovember19,2026,andanoverallstudycompletiondateofNovember05,2029.[7,19]RecruitmentintheEU/EEAalsobeganonNovember7,2023,withanestimatedtrialenddateinthisregionofAugust1,2026.[21]∗∗TheNeoPSMATrial(NCT06881823)∗∗ThisPhaseI/IIstudyisdesignedtoevaluateboth[^{177}Lu]Lu−PSMA−R2(AAA602)and[225Ac]Ac−PSMA−R2(AAA802)asneoadjuvanttreatmentspriortoradicalprostatectomyandpelviclymphnodedissection.[8,9]Theprimaryobjectivesincludedeterminingthesafety,tolerability,anti−tumoractivity,pharmacokinetics,anddosimetryoftheseagentsintheneoadjuvantsetting.[9]Thetrialplanstoenrollanestimated228malepatientswithPSMA−positivehigh−risklocalizedprostatecancer(HRLPC).[9]EnrollmentisanticipatedtobegininJune2025.[8,9]ThedesignoftheSatisfACtiontrial,featuringthreedistinctpatientpopulations(mCRPCpost−^{177}Lu,mCRPCpre−^{177}Lu,andmHSPCpre−^{177}Lu)[6,20,21],isastrategicallyrobustapproach.ItenablesNovartistoconcurrentlygathercrucialsafetyandefficacydatafor[225Ac]Ac−PSMA−R2acrossvariedstagesofprostatecancerprogressionanddifferentpriortreatmentlandscapes.SuccessinthemCRPCpost−^{177}Lucohortwouldaddressasignificantunmetmedicalneed,potentiallypositioning[225Ac]Ac−PSMA−R2asaviabletherapeuticoptionfollowingfailureofaPSMA−targetedbeta−emitter,likelyowingtothesuperiorpotencyofalpha−particleradiation.ThemCRPCpre−^{177}$Lu cohort allows for an assessment of [225Ac]Ac-PSMA-R2 as a primary RLT option, potentially offering an alternative or even superior initial RLT strategy. Investigating the agent in mHSPC represents a significant step towards earlier lines of therapy; positive outcomes in this group could substantially alter the treatment paradigm for mHSPC, where achieving durable responses remains a key objective. This multi-cohort strategy maximizes the information yield from a Phase I/II study and will be instrumental in guiding the design of subsequent Phase III trials and defining the optimal target patient populations.

[Concurrently, the NeoPSMA trial 8, which will assess [225Ac]Ac-PSMA-R2 (alongside its Lutetium-177 counterpart) in the neoadjuvant setting for high-risk localized prostate cancer, is a forward-looking initiative. Neoadjuvant therapies aim to reduce tumor volume, eradicate micrometastatic disease, and thereby improve the outcomes of definitive local treatments such as surgery. If [225Ac]Ac-PSMA-R2 demonstrates the ability to effectively decrease tumor burden in high-risk localized disease with an acceptable toxicity profile, it could lead to increased rates of complete surgical resection, reduced rates of biochemical recurrence, and potentially obviate or defer the necessity for adjuvant treatments. This application represents a significant departure from its use in metastatic settings and could establish a new, earlier therapeutic niche for PSMA-targeted RLT. The inclusion of both $^{177}$Lu and $^{225}$Ac versions of the PSMA-R2 ligand in the NeoPSMA trial will also allow for a valuable comparison of beta versus alpha emitters in this specific clinical context.]

[**Table 2: Key Clinical Trials for [225Ac]Ac-PSMA-R2**]

[| NCT ID | Trial Name/Acronym | Phase | Status | Primary Objectives (Abbreviated) | Patient Population |]

[| :--- | :--- | :--- | :--- | :--- | :--- |]

[| NCT05983198 6 | SatisfACtion 7 | I/II | Recruiting 7 | Dose Esc: Safety, MTD/RDE. Dose Exp: Anti-tumor activity (ORR). 1 | PSMA+ mHSPC & mCRPC (pre- & post-$^{177}$Lu-PSMA RLT) 1 |]

[| NCT06881823 8 | NeoPSMA 8 | I/II | Planned (Enroll. June 2025) 8 | Neoadjuvant: Safety, tolerability, anti-tumor activity, PK, dosimetry of [225Ac]Ac-PSMA-R2 & [$^{177}$Lu]Lu-PSMA-R2.9 | PSMA+ High-Risk Localized Prostate Cancer (HRLPC) 9 |]

6. Clinical Efficacy of [225Ac]Ac-PSMA-R2 and Related Therapies

The clinical efficacy of [225Ac]Ac-PSMA-R2 is currently under investigation, and specific interim results from the ongoing SatisfACtion (NCT05983198) or the planned NeoPSMA (NCT06881823) trials, such as Prostate-Specific Antigen (PSA) response rates, Overall Response Rates (ORR), Progression-Free Survival (PFS), and Overall Survival (OS), are not yet available in the public domain through the provided information.[7] The primary focus of the initial dose-escalation phase of NCT05983198 is to establish the safety profile and determine the MTD/RDE, with efficacy being a key objective for the subsequent dose-expansion phase.[1]

However, valuable insights into the potential efficacy of [225Ac]Ac-PSMA-R2 can be extrapolated from the broader clinical experience with other $^{225}$Ac-PSMA radioligand therapies, predominantly those utilizing the PSMA-617 ligand or similar constructs. These studies provide a benchmark for what might be expected from this class of agents.

Extrapolated Efficacy from General $^{225}$Ac-PSMA RLT Studies:

  • PSA Response (≥50% decline from baseline, PSA50):
  • A systematic review encompassing 10 articles with 256 patients (primarily treated with $^{225}$Ac-PSMA-617) reported a pooled PSA50 response rate of 62.8%.[5]
  • A more extensive systematic review and meta-analysis involving 18 studies and 1,155 patients (again, mainly $^{225}Ac−PSMA−617andanalogousagents)foundapooledPSA50responserateof65∗Thismeta−analysisalsohighlightedthatPSA50responseratesvariedsignificantlybasedonthenumberofpriorlinesoftreatment:82∗Furthermore,patientswhowerenaı¨vetoandrogenreceptorpathwayinhibitors(ARPIs)demonstratedan83^{177}$Lu-PSMA-617, respectively).[3]
  • A separate study focusing on $^{225}$Ac-PSMA-617 in 29 mCRPC patients reported a PSA decline of ≥50% in 62.1% of participants.[23]
  • Molecular Response/Overall Response Rate (ORR):
  • One systematic review indicated that a molecular response, as assessed by $^{68}$Ga-PSMA PET/CT imaging, was observed in 74% of patients treated with $^{225}$Ac-PSMA RLT.[5]
  • The study of 29 patients treated with $^{225}$Ac-PSMA-617 reported disease control, based on molecular imaging response criteria, in 61.1% of cases.[23]
  • Progression-Free Survival (PFS):
  • The pooled median PFS from one review was 9.1 months.[5]
  • The larger meta-analysis reported a range of median PFS from 3 to 15 months across the included studies.[3]
  • The study on $^{225}$Ac-PSMA-617 estimated a median PFS of 8 months.[23]
  • Overall Survival (OS):
  • A pooled median OS of 12.8 months was reported in one systematic review.[5]
  • The meta-analysis found a range of median OS from 8 to 31 months across different studies.[3]
  • An estimated median OS of 18 months was observed in the $^{225}$Ac-PSMA-617 study of 29 patients.[23]

The collective data from various $^{225}$Ac-PSMA RLT investigations, primarily with the PSMA-617 ligand, suggest substantial anti-tumor activity in mCRPC, with PSA50 response rates consistently around 60-65% and encouraging PFS and OS figures.[3] A significant observation emerging from these studies is the potentially greater efficacy in patients who are less heavily pre-treated.[3] This implies that factors such as a lower overall tumor burden, reduced clonal heterogeneity within tumors, better preserved bone marrow function, or the absence of acquired resistance mechanisms to prior therapies might contribute to enhanced sensitivity to alpha-particle therapy. This observation has important implications for the clinical development strategy of [225Ac]Ac-PSMA-R2. Firstly, it provides a strong rationale for the NeoPSMA trial (NCT06881823), which investigates [225Ac]Ac-PSMA-R2 in the neoadjuvant setting for localized prostate cancer, an inherently earlier disease stage.[8] Secondly, it suggests that if [225Ac]Ac-PSMA-R2 demonstrates a favorable safety and efficacy profile, its optimal positioning within the mCRPC treatment algorithm might be earlier, or it could even find a role in mHSPC, as is being explored in the respective cohorts of the SatisfACtion trial.[6] Lastly, the efficacy observed in patients who have previously progressed on $^{177}$Lu-PSMA therapy (PSA50 of 54% [3]), while somewhat lower than in RLT-naïve patients, still indicates that a meaningful proportion of these individuals can derive benefit from subsequent $^{225}$Ac-PSMA therapy, positioning it as a potential sequential treatment option.

Table 3: Summary of Efficacy Outcomes for $^{225}$Ac-PSMA Therapies in mCRPC (Primarily $^{225}$Ac-PSMA-617 and similar, pending [225Ac]Ac-PSMA-R2 specific data)

EndpointReported Rate/DurationKey Influencing Factors (Examples)Source(s)
PSA50 Response (≥50% PSA decline)Pooled: 62-65%Prior lines of treatment (higher in less pre-treated), ARPI/chemo/RLT-naïve status3
Molecular Response/ORR (Imaging based)~61-74%-5
Median PFSPooled: 9.1 months (Range: 3-15 months)Patient baseline characteristics, prior therapies3
Median OSPooled: 12.8 months (Range: 8-31 months)Patient baseline characteristics, prior therapies3

7. Safety and Tolerability Profile

The safety and tolerability of [225Ac]Ac-PSMA-R2 are critical aspects being evaluated in its ongoing clinical development. Specific adverse event data from the SatisfACtion (NCT05983198) or the planned NeoPSMA (NCT06881823) trials are not yet publicly detailed, as these studies are in relatively early stages.[1] The SatisfACtion trial protocol explicitly includes close monitoring for side effects, their severity, necessary treatment adjustments, and changes in laboratory parameters as primary endpoints for the dose-escalation phase.[1]

Information regarding the safety profile of the general class of $^{225}$Ac-PSMA RLT agents (largely based on $^{225}$Ac-PSMA-617 and similar compounds) provides an indication of potential adverse events:

  • Xerostomia (Dry Mouth): This is the most frequently reported adverse event of any grade, occurring in 72.7% to 79.3% of patients in various reviews and studies.[3] The majority of cases are mild to moderate (Grade 1-2). Severe (Grade ≥3) xerostomia is uncommon, reported in approximately 1.2% to 2% of patients.[3] For $^{225}$Ac-PSMA-617, xerostomia can become a dose-limiting toxicity if the administered activity per cycle exceeds 100 kBq/kg.[17] This side effect is attributed to PSMA expression in the salivary glands, leading to their unintended irradiation.[3]
  • Hematological Toxicity: Myelosuppression is a significant concern.
  • Anemia: Grade ≥3 anemia has been reported in 11% to 12.3% of patients in meta-analyses.[3] One study reported Grade 3 anemia in 21.1% of patients.[24]
  • Thrombocytopenia: Grade ≥3 thrombocytopenia occurred in 6% to 6.3% of patients.[3] Grade 3/4 thrombocytopenia was seen in 19.7% in one specific study.[24]
  • Leukopenia: Grade ≥3 leukopenia was reported in 8.3% of patients [5], with Grade 3 leukocytopenia at 8.4% in another study.[24] Hematological toxicities are often more pronounced in patients with severe bone marrow involvement by metastatic disease or those who have received extensive prior chemotherapy.[24]
  • Nephrotoxicity: Renal toxicity (Grade ≥3) has been reported in approximately 3.8% of patients.[5] One study noted Grade 3 nephrotoxicity in 1.4% of its cohort.[24]
  • Hepatotoxicity: Grade 3 hepatotoxicity was observed in 8.4% of patients in one study.[24]
  • Fatigue: This is a common but generally mild to moderate side effect.
  • Nausea and Vomiting: These occur less frequently and with less severity than typically seen with some cytotoxic chemotherapies.
  • Flare Pain: An acute increase in tumor-related pain shortly after administration was reported as the most common adverse event immediately following radiopharmaceutical administration in one retrospective study.[24]

Overall, a large meta-analysis indicated that the majority (89%) of all reported side effects associated with $^{225}$Ac-PSMA RLT were mild (Grade 1-2).[3] Treatment discontinuation due to adverse events varied across studies, with rates ranging from 3.6% to 31%.[3]

Regarding the diagnostic analog, $^{68}$Ga-PSMA-R2, used for imaging, studies have shown it to be well tolerated. In an evaluation of 30 patients, no drug-related treatment-emergent adverse events were reported.[4] A total of 13 mild or moderate adverse events occurred in 7 participants, with one serious adverse event (ileus) deemed unrelated to the study drug. The most common adverse events observed in more than 5% of participants were fatigue (10%) and rash (6.7%).[4]

The high incidence of xerostomia [3] represents a significant challenge impacting the quality of life for patients undergoing $^{225}$Ac-PSMA RLT. Although often manageable, its prevalence highlights the clinical consequence of PSMA expression in salivary glands and their subsequent irradiation by the alpha particles. The purported "optimized biodistribution" of the PSMA-R2 ligand [10] and the observed lower salivary gland uptake with its $^{68}$Ga-labeled counterpart [4] are therefore of considerable interest. If [225Ac]Ac-PSMA-R2 can indeed demonstrate reduced salivary gland accumulation compared to agents like $^{225}$Ac-PSMA-617 (which has shown high estimated salivary gland doses [17]), it could potentially lessen the incidence or severity of xerostomia. This would be a critical advantage for improving the tolerability of PSMA-targeted alpha therapy.

The occurrence of Grade ≥3 hematological toxicities, such as anemia, thrombocytopenia, and leukopenia [3], especially in patients with a history of prior chemotherapy or those with extensive bone marrow infiltration by the tumor [24], underscores the necessity for meticulous patient selection and vigilant hematological monitoring. Bone marrow is a highly radiosensitive tissue. Off-target radiation to the bone marrow or the irradiation of marrow already compromised by tumor involvement can lead to significant myelosuppression. This emphasizes the importance of comprehensive baseline hematological assessments and regular blood count monitoring throughout the course of [225Ac]Ac-PSMA-R2 therapy, as stipulated in the clinical trial protocols.[1] The determination of the MTD and RDE in the SatisfACtion trial will be heavily influenced by the incidence and severity of these hematological adverse events.

Table 4: Common Adverse Events Associated with $^{225}$Ac-PSMA Radioligand Therapy (General Profile, pending [225Ac]Ac-PSMA-R2 specific data)

Adverse EventTypical Frequency (Any Grade)Typical Frequency (Grade ≥3)NotesSource(s)
Xerostomia (Dry Mouth)70-80%1-2%Most common AE; can be dose-limiting for some $^{225}$Ac-PSMA agents.3
AnemiaCommon11-21%More frequent in heavily pre-treated patients.3
ThrombocytopeniaCommon6-20%3
Leukopenia/NeutropeniaCommon~8%5
FatigueCommonInfrequentGenerally mild to moderate.3
NauseaLess CommonRare3
NephrotoxicityInfrequent~1-4%Cumulative dose concern.5
Flare PainVariableInfrequentAcute post-administration phenomenon.24

8. Pharmacokinetics, Biodistribution, and Dosimetry

Understanding the pharmacokinetic (PK) profile, biodistribution patterns, and radiation dosimetry of [225Ac]Ac-PSMA-R2 is essential for optimizing its therapeutic use and ensuring patient safety. While specific data for the $^{225}$Ac-labeled PSMA-R2 are still emerging from ongoing clinical trials, information from its $^{68}Ga−labeleddiagnosticcounterpart(^{68}$Ga-PSMA-R2) provides valuable preliminary insights. Pharmacokinetics and dosimetry are listed as objectives in the SatisfACtion (secondary) and NeoPSMA (primary) trials, respectively.[1]

[Pharmacokinetics (PK):]

[Specific PK parameters for [225Ac]Ac-PSMA-R2 are yet to be published. However, studies with $^{68}$Ga-PSMA-R2 have yielded the following PK characteristics in humans 4:]

  • Absorption and Distribution: Following intravenous injection, $^{68}$Ga-PSMA-R2 is rapidly distributed. It was detected in the blood from approximately 5 minutes (0.083 hours) up to 6 hours post-injection. Peak blood concentrations are typically observed around 5 minutes after administration, followed by a steady decline over the subsequent 6 hours. The apparent volume of distribution has been reported in the range of 18,300–25,200 mL.
  • Elimination: The primary route of elimination for $^{68}$Ga-PSMA-R2 appears to be renal. Urinary excretion accounted for 44% to 81% of the total administered activity within 6 hours post-injection. The total systemic clearance was reported as 3,730–8,330 mL/h.
  • Half-life: The terminal half-life of $^{68}$Ga-PSMA-R2 in the blood is approximately 2–4 hours. Animal studies using $^{68}$Ga-PSMA-R2 indicated good stability in blood, with 89% of the radiotracer remaining as the intact parent compound one-hour post-injection.[25]

Biodistribution (Primarily from $^{68}$Ga-PSMA-R2 Data):

  • Tumor Uptake: $^{68}$Ga-PSMA-R2 PET/CT imaging has effectively visualized PSMA-positive lesions in prostate cancer patients. In one study, 85 lesions were detected at 1 hour and 103 lesions at 2 hours post-injection in 22 participants.[4] Qualitative imaging showed that the contrast of tumors increased over time, with the steepest incline in uptake observed within the first few minutes after injection.[25]
  • Normal Organ Uptake: The biodistribution of $^{68}$Ga-PSMA-R2 in normal organs is a critical indicator of potential sites for off-target radiation exposure with the therapeutic analog.[4]
  • The highest physiological uptake was observed in the urinary bladder wall (due to excretion) and the kidneys.
  • Notably, uptake in the salivary glands and lacrimal glands was reported to be relatively low.
  • Mean non-decay-corrected tissue activity was higher in the liver and kidneys compared to other organs.
  • Over time, an exponential decrease in the percentage of injected activity was observed in the brain, heart wall, kidneys, liver, lungs, salivary glands, and spleen. An earlier dosimetry study with $^{68}$Ga-PSMA-R2 also reported no significant bone uptake at 4 hours, suggesting a low profile of radiometabolites that might otherwise accumulate in bone.[25] The generally high uptake in lacrimal and salivary glands common to many PSMA PET tracers can lead to xerostomia when these ligands are labeled with therapeutic radionuclides; thus, the comparatively lower uptake of $^{68}Ga−PSMA−R2intheseglandsisapromisingfeature.[4,11]∗∗RadiationDosimetry:∗∗∗∗∗[225Ac]Ac−PSMA−R2:∗∗Patient−specificdosimetryfor[225Ac]Ac−PSMA−R2isanobjectiveoftheNeoPSMAclinicaltrial.[9]Detailedhumandosimetrydataforthisspecifictherapeuticagentarenotyetavailable.∗∗∗^{68}Ga−PSMA−R2Dosimetry(fromPhase1data[4,11,16]):∗∗∗Thehighestmeanabsorbedradiationdosesweredeliveredtotheurinarybladderwall(0.120mGy/MBq)andthekidneys(0.061mGy/MBq).∗Meanabsorbeddosetothesalivaryglandswas0.016mGy/MBq.∗Meanabsorbeddosetothelacrimalglandswas0.008mGy/MBq.∗Nootherorganreceivedameanabsorbeddoseexceeding0.020mGy/MBq.∗Themeaneffectivewhole−bodydosewascalculatedtobe0.015mSv/MBq.∗∗∗^{225}$Ac-PSMA-617 Dosimetry (for comparison, assuming a Relative Biologic Effectiveness (RBE) of 5 for alpha particles [17]):**
  • For 1 MBq of $^{225}$Ac-PSMA-617, estimated mean absorbed doses were:
  • Salivary glands: 2.3 Sv
  • Kidneys: 0.7 Sv
  • Red marrow: 0.05 Sv

The pharmacokinetic and dosimetry data derived from $^{68}$Ga-PSMA-R2 studies are encouraging for the therapeutic development of [225Ac]Ac-PSMA-R2.[4] The observed rapid blood clearance and significant urinary excretion are generally favorable characteristics for a radiopharmaceutical, as they can help reduce non-target radiation exposure. Of particular importance is the reported lower radiation dose to the salivary and lacrimal glands with $^{68}$Ga-PSMA-R2 compared to the kidneys and bladder. While direct comparison of absorbed doses between $^{68}$Ga-PSMA-R2 (a diagnostic positron emitter) and $^{225}$Ac-PSMA-617 (a therapeutic alpha emitter) is complex due to different particle types, energies, RBEs, and potential differences in ligand chemistry, the initial findings for PSMA-R2 suggest a potentially more favorable biodistribution concerning salivary gland uptake. If this characteristic is maintained with the $^{225}$Ac conjugate, it could translate into significantly reduced radiation doses to these sensitive organs, potentially mitigating the severity of xerostomia, a common and debilitating side effect associated with other $^{225}$Ac-PSMA therapies like $^{225}$Ac-PSMA-617.[17] This represents a key potential advantage for the PSMA-R2 ligand platform. However, it is important to acknowledge that subtle differences in the chelator chemistry and the size or charge of the metal-ligand complex (Gallium vs. Actinium) can sometimes lead to variations in in vivo behavior, so direct translation of biodistribution from the $^{68}$Ga-labeled agent to the $^{225}$Ac-labeled agent requires confirmation through dedicated studies with [225Ac]Ac-PSMA-R2.

While population-based dosimetry estimates, such as those available for $^{225}$Ac-PSMA-617 [17] and $^{68}$Ga-PSMA-R2 [4], are valuable for initial assessments, the unique properties of alpha particles—specifically their high LET and very short range in tissue—make individual variations in radiopharmaceutical uptake and patient-specific organ morphology particularly critical. The inclusion of dosimetry as a formal objective in clinical trials like NeoPSMA [9] is therefore essential for the safe and effective development of [225Ac]Ac-PSMA-R2. Alpha particles deliver highly localized and intense radiation. Consequently, even minor variations in the amount of radiopharmaceutical accumulating in a tumor or a critical normal organ, or differences in the size, shape, and proximity of that organ to targeted tumor sites, can result in significant variations in the actual absorbed dose and the resultant biological effect. Therefore, advancing towards patient-specific dosimetry—possibly utilizing imaging with a matched diagnostic/theranostic pair like $^{226}$Ac as a surrogate for $^{225}$Ac (as suggested for Ac-TATE compounds [12]), or by careful extrapolation from serial $^{68}$Ga-PSMA-R2 imaging—will be crucial. This personalized approach will help tailor [225Ac]Ac-PSMA-R2 administered activities to maximize tumor cell kill while rigorously adhering to normal tissue radiation tolerance limits. This level of precision is arguably more critical for alpha emitters than for beta emitters due to the steep dose-response relationships and the limited therapeutic reach of the crossfire effect from alpha particles.

9. Regulatory Status and Future Perspectives

[225Ac]Ac-PSMA-R2 is currently an investigational drug and has not yet received marketing approval from major regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is in the Phase I/II stages of clinical development.[1] The agent is classified as a New Molecular Entity.[8] According to available information, [225Ac]Ac-PSMA-R2 does not currently hold Orphan Drug Status.[8] For context, while not specific to [225Ac]Ac-PSMA-R2, another investigational $^{225}$Ac-PSMA agent, $^{225}$Ac-FL-020, received Fast Track designation from the FDA, indicating regulatory acknowledgment of the potential of PSMA-targeted alpha therapies to address the unmet medical need in mCRPC.[26]

[Potential Role in the Evolving Treatment Landscape of Prostate Cancer:]

[Should [225Ac]Ac-PSMA-R2 demonstrate a favorable benefit-risk profile in ongoing and future clinical trials, it could emerge as a significant therapeutic option across various stages of prostate cancer:]

  • Heavily Pre-treated mCRPC: For patients who have progressed on multiple lines of therapy, including $^{177}$Lu-PSMA RLT (as being studied in Group 1 of the SatisfACtion trial, NCT05983198).[6]
  • Earlier Lines of mCRPC Treatment: For patients with mCRPC who are naïve to $^{177}$Lu-PSMA RLT (Group 2 of NCT05983198) [6], potentially offering a potent first RLT option.
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): An earlier disease setting where new effective treatments are sought (Group 3 of NCT05983198).[6]
  • Neoadjuvant Setting for High-Risk Localized Prostate Cancer: To improve outcomes of definitive local therapies like surgery (as planned in the NeoPSMA trial, NCT06881823).[8] The high potency of $^{225}$Ac may be particularly advantageous for patients with aggressive disease phenotypes or those with diffuse red marrow infiltration, where the efficacy of other therapies might be compromised.[27]

[Ongoing Research and Unanswered Questions:]

[The clinical development of [225Ac]Ac-PSMA-R2 aims to address several critical questions:]

  • Determination of the optimal dosing schedule, including the activity per cycle and the number of cycles, for different patient populations.
  • Comprehensive characterization of the long-term safety profile, particularly focusing on cumulative toxicities with repeated administrations.
  • Comparative efficacy versus other PSMA-targeted therapies (e.g., $^{177}$Lu-PSMA-R2, $^{177}$Lu-PSMA-617, other emerging PSMA ligands) and potentially other classes of systemic agents.
  • Identification and validation of biomarkers (e.g., baseline PSMA expression levels via PET imaging, genomic markers) to predict patient response and potential resistance mechanisms.
  • Exploration of rational combination therapies, potentially with immunotherapy agents, DNA damage repair inhibitors, or ARPIs, to enhance efficacy or overcome resistance.
  • Development of effective strategies for the management and mitigation of common side effects, especially xerostomia and hematological toxicities.

The development pathway for [225Ac]Ac-PSMA-R2, which encompasses investigations from heavily pretreated mCRPC through to the neoadjuvant setting for localized disease [6], reflects Novartis's significant ambition for this agent. However, translating the "promising efficacy and acceptable safety profile" observed in broader $^{225}$Ac-PSMA RLT studies [3] into a practice-changing therapy specifically for [225Ac]Ac-PSMA-R2 will necessitate robust and conclusive data from the ongoing Phase I/II trials and, subsequently, from well-designed, adequately powered randomized controlled trials. Early-phase trials, such as SatisfACtion, are crucial for establishing initial safety parameters, determining appropriate dosing, and obtaining preliminary signals of efficacy. The definitive test of clinical value, however, typically comes from larger Phase III trials that compare the investigational agent against established standards of care or other active comparators. Key challenges that [225Ac]Ac-PSMA-R2 must overcome include demonstrating a clear and clinically meaningful benefit (e.g., improvement in overall survival, progression-free survival, or quality of life) that justifies its adoption. Effective management of toxicities, particularly potential long-term effects such as persistent xerostomia and possible renal or hematological compromise, will be paramount, especially if the PSMA-R2 ligand does not fully mitigate these concerns compared to other $^{225}$Ac-based agents. Additionally, practical considerations such as the complexities of Actinium-225 production, supply chain logistics, and the overall cost-effectiveness of the therapy will play significant roles in its eventual clinical integration. The comprehensive clinical development plan currently underway [6] suggests that Novartis is systematically collecting data across diverse patient populations to identify the optimal clinical niche(s) where [225Ac]Ac-PSMA-R2 can provide the greatest benefit to patients with prostate cancer.

10. Expert Conclusion and Outlook

[225Ac]Ac-PSMA-R2 is an investigational targeted alpha therapy that stands at a promising juncture in the evolving landscape of prostate cancer treatment. Developed by Novartis, this agent combines the PSMA-R2 ligand, designed for potentially enhanced tumor targeting and favorable biodistribution, with the highly potent alpha-emitting radionuclide Actinium-225. Its mechanism of action relies on the specific delivery of $^{225}$Ac to PSMA-expressing cancer cells, where the emission of high-energy alpha particles induces lethal double-strand DNA breaks. Currently, [225Ac]Ac-PSMA-R2 is advancing through Phase I/II clinical trials, notably the SatisfACtion study (for mCRPC and mHSPC) and the planned NeoPSMA study (for neoadjuvant treatment of high-risk localized prostate cancer).

While specific efficacy and detailed safety data for [225Ac]Ac-PSMA-R2 are still emerging from these dedicated trials, the broader clinical experience with other $^{225}$Ac-PSMA therapies, predominantly using the PSMA-617 ligand, has demonstrated significant anti-tumor activity. Pooled data suggest PSA50 response rates in the range of 60-65% in mCRPC patients, with encouraging, albeit variable, progression-free and overall survival outcomes. However, these therapies also highlight key toxicities, most notably xerostomia due to salivary gland uptake of PSMA ligands, and hematological suppression. Pharmacokinetic and dosimetry studies using the diagnostic analog $^{68}$Ga-PSMA-R2 have indicated favorable characteristics for the PSMA-R2 ligand, including potentially lower salivary gland uptake compared to some other PSMA-targeting agents. If these attributes translate to the $^{225}$Ac therapeutic conjugate, [225Ac]Ac-PSMA-R2 could offer an improved therapeutic index.

The therapeutic potential of [225Ac]Ac-PSMA-R2 is considerable. Its high-LET alpha particles offer a distinct advantage in overcoming resistance mechanisms and effectively killing cancer cells, making it a particularly attractive option for patients with advanced, aggressive, or heavily pre-treated prostate cancer. If the PSMA-R2 ligand indeed confers superior biodistribution, especially with reduced accumulation in sensitive normal tissues like salivary glands, it could lead to a more tolerable side effect profile compared to other $^{225}$Ac-PSMA agents, which would be a significant clinical advancement.

However, several challenges must be addressed. The foremost is the management of toxicity; while potentially mitigated by PSMA-R2, xerostomia will likely remain a concern requiring proactive management strategies. Hematological and renal toxicities also necessitate careful patient selection and vigilant monitoring. Identifying patients who are most likely to benefit from this potent therapy while minimizing the risk of severe adverse events will be crucial, likely involving biomarkers related to PSMA expression levels, tumor heterogeneity, and baseline organ function. Determining the optimal placement of [225Ac]Ac-PSMA-R2 within the complex prostate cancer treatment sequence—whether before or after other systemic therapies like $^{177}$Lu-PSMA RLT, chemotherapy, or ARPIs—and exploring rational combination strategies to further enhance efficacy or overcome resistance are key areas for ongoing and future research. Finally, the logistical aspects of Actinium-225 production, its relatively short half-life, and ensuring widespread accessibility if the drug gains approval, are practical hurdles that will need to be overcome.

The future trajectory of [225Ac]Ac-PSMA-R2 will be heavily influenced by the outcomes of the current Phase I/II trials. Positive results will undoubtedly pave the way for larger, potentially registrational Phase III studies. Future research will likely concentrate on optimizing dosing regimens, further investigating combination therapies, and refining patient selection criteria through predictive biomarkers. The exploration of [225Ac]Ac-PSMA-R2 in the neoadjuvant setting, as planned in the NeoPSMA trial, represents an exciting frontier that could potentially shift PSMA-targeted RLT to earlier stages of prostate cancer management, where it might have an even greater impact.

Ultimately, the success of [225Ac]Ac-PSMA-R2 hinges on a delicate balance between the profound cytotoxic potency of Actinium-225 and the precision of the PSMA-R2 targeting ligand. Alpha-emitters offer a powerful tool against cancer, but their therapeutic utility is critically dependent on the ability of the delivery system to concentrate this power specifically at the tumor site while sparing healthy tissues. The "optimized biodistribution" attributed to PSMA-R2 [10] and the favorable dosimetry profile of $^{68}$Ga-PSMA-R2 [4] offer hope in this regard. However, definitive confirmation with the therapeutic [225Ac]Ac-PSMA-R2 agent through comprehensive clinical trial data, particularly focusing on long-term safety and patient-specific dosimetry, will be paramount in determining if this agent can achieve a clinically meaningful improvement in the therapeutic index over existing and emerging treatments for prostate cancer.

Works cited

  1. 225Ac-Psma-R2 – Application in Therapy and Current Clinical ..., accessed May 19, 2025, https://clinicaltrials.eu/inn/225ac-psma-r2/
  2. Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy - Clinical trials, accessed May 19, 2025, https://clinicaltrials.eu/trial/study-of-225acac-psma-r2-for-men-with-advanced-prostate-cancer-previously-treated-or-not-with-177lu-psma-therapy/
  3. Time for action: actinium-225 PSMA-targeted alpha therapy for ..., accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11905128/
  4. Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an ..., accessed May 19, 2025, https://jnm.snmjournals.org/content/early/2025/02/06/jnumed.124.268318
  5. Evolving role of 225Ac-PSMA radioligand therapy in metastatic ..., accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/33746213/
  6. Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT - NCI, accessed May 19, 2025, https://www.cancer.gov/clinicaltrials/NCI-2025-02649
  7. Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate ..., accessed May 19, 2025, https://www.novartis.com/clinicaltrials/study/nct05983198
  8. 225 Ac PSMA R2 - Novartis Pharmaceuticals - AdisInsight - Springer, accessed May 19, 2025, https://adisinsight.springer.com/drugs/800075025
  9. Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC (NeoPSMA) - ClinicalTrials.Veeva, accessed May 19, 2025, https://ctv.veeva.com/study/study-to-assess-177lu-lu-psma-r2-aaa602-and-225ac-ac-psma-r2-aaa802-in-participants-with-psma
  10. Lutetium-177 PSMA-R2 for Prostate Cancer | Open Medscience, accessed May 19, 2025, https://openmedscience.com/the-development-of-lutetium-177-psma-r2-a-novel-therapeutic-agent-for-prostate-cancer/
  11. Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer - PMC - PubMed Central, accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11876733/
  12. Preclinical Evaluation of Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy - Journal of Nuclear Medicine, accessed May 19, 2025, https://jnm.snmjournals.org/content/early/2024/10/03/jnumed.124.267999.full.pdf
  13. Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer - PMC, accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8882883/
  14. Safety, Dosimetry, and Feasibility of [ 68 Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer | Request PDF - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/publication/388785106_Safety_Dosimetry_and_Feasibility_of_68_GaGa-PSMA-R2_as_an_Imaging_Agent_in_Patients_with_Biochemical_Recurrence_or_Metastatic_Prostate_Cancer
  15. Gallium (68Ga) psma-R2 | C41H60BrGaN8O15 | CID 163203566 - PubChem, accessed May 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Gallium-_68Ga_-psma-R2
  16. Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer - Journal of Nuclear Medicine, accessed May 19, 2025, https://jnm.snmjournals.org/content/early/2025/02/20/jnumed.124.268318.full.pdf
  17. Targeted α-Therapy of Metastatic Castration-Resistant Prostate ..., accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/28408529/
  18. PSMA and Beyond 2025: PSMA-I&T vs PSMA-617: Is There a Difference? - UroToday, accessed May 19, 2025, https://www.urotoday.com/conference-highlights/2025-ucsf-ucla-psma-conference/159352-psma-and-beyond-2025-psma-i-t-vs-psma-617-is-there-a-difference-2.html
  19. Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT - LarvolClin, accessed May 19, 2025, https://clin.larvol.com/trial-detail/NCT05983198
  20. Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT | Clinical Research Trial Listing - CenterWatch, accessed May 19, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05983198/phase-i-ii-study-of-225acac-psma-r2-in-psma-positive-prostate-cancer-withwithout-prior-177lu-psma-rlt
  21. Clinical Trials in the European Union - EMA, accessed May 19, 2025, https://euclinicaltrials.eu/ctis-public/view/2023-507672-52-00
  22. Phase I/​II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/​Without Prior 177Lu-PSMA RLT - Mayo Clinic, accessed May 19, 2025, https://www.mayo.edu/research/clinical-trials/cls-20582084
  23. The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/40094004/
  24. Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer - PubMed, accessed May 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39941774/
  25. The chemical structures of PSMA-targeting imaging agents - ResearchGate, accessed May 19, 2025, https://www.researchgate.net/figure/The-chemical-structures-of-PSMA-targeting-imaging-agents-GaGa-FAlF-P16-093_fig1_377357416
  26. FDA grants fast track designation to 225Ac-FL-020 in mCRPC - Urology Times, accessed May 19, 2025, https://www.urologytimes.com/view/fda-grants-fast-track-designation-to-225ac-fl-020-in-mcrpc
  27. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer | Journal of Nuclear Medicine, accessed May 19, 2025, https://jnm.snmjournals.org/content/early/2016/07/06/jnumed.116.178673

Published at: May 19, 2025

This report is continuously updated as new research emerges.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy